Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Conditions: Leukemia; Brain Tumor; Solid Tumor; Lymphoma Interventions: Drug: ALRN-6924; Drug: Cytarabine Sponsor: Dana-Farber Cancer Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials